StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report sent to investors on Sunday. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets decreased their price objective on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a report on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

Shares of NovaBay Pharmaceuticals stock opened at $0.71 on Friday. NovaBay Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $12.07. The firm has a market capitalization of $3.50 million, a PE ratio of -0.01 and a beta of 0.73. The company’s fifty day moving average price is $0.64 and its two-hundred day moving average price is $1.59.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.